Clinical evaluation of anti-malarial monoclonal antibodies in Africa
Voices in Infection Biology
- Datum: 10.11.2023
- Uhrzeit: 15:00
- Vortragende(r): Peter Crompton
- NIH: National Institute of Allergy and Infectious Diseases (NIAID)
- Ort: Max Planck Institute for Infection Biology and via Zoom
- Raum: Seminar Room 1st Floor
- Gastgeber: Silvia Portugal
- Kontakt: vseminars@mpiib-berlin.mpg.de
If you are interested in joining the seminar, please contact: vseminars@mpiib-berlin.mpg.de. You will receive an automatic reply containing the Zoom link for the seminar.
Would you like to regularly receive the Zoom link for upcoming Voices in Infection Biology seminars as well as event updates from the Max Planck Institute for Infection Biology? Subscribe to our Newsletter!
New tools are needed to reduce malaria morbidity and mortality in the highest risk populations including infants, children, and pregnant women. Recent early phase clinical trials have highlighted the potential utility of anti-sporozoite monoclonal antibodies in preventing P. falciparum infection for defined time periods in high-risk populations. This presentation will summarize the clinical development of the anti-sporozoite monoclonal antibodies CIS43LS and L9LS in Africa.